Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
You may also be interested in...
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.
In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.